Abbott Reports Results of TactiCath SE in (PERSIST-END) Study for the Treatment of Persistent Atrial Fibrillation
- The (PERSIST-END) study evaluating TactiCath SE in 224 patients with persistent AFib across 21 sites in the US & Australia for 15mos.
- The results showed that 9 of 10 patients (89%) remained symptom-free for ~15mos, patients experienced an improved QoL & ≥50% reduction in the use of health care resources due to the more effective therapy. The results were presented at HRS 2022
- The trial met safety, effectiveness & QoL EPs i.e., primary effectiveness EPs were reported in 61.6% of patients remained free from arrhythmia recurrence, new or increased Class I/III AAD, repeat ablation or cardioversion, the rate of SAEs was 3.1% which is consistent with other studies in the same indication
Ref: Abbott | Image: Abbott
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].